Long-term Evaluation of Viability of Microfilariae and Iv Transplanted Adult Dirofilaria Immitis in Microfilaraemic Dogs Treated With Low-dose, Short- and Long-treatment Regimens of Doxycycline and Ivermectin

John Wilson McCall (jwmccall@uga.edu)
TRS Labs, Inc

Abdelmoneim Mansour
TRS Labs, Inc

Utami DiCosty
TRS Labs, Inc

Crystal Fricks
TRS Labs, Inc

Scott McCall
TRS Labs, Inc

Michael Timothy Dzimianski
University of Georgia

Ben Carson
TRS Labs, Inc

Research Article

Keywords: Dirofilaria immitis, mosquitoes, migration, development, dogs, doxycycline, ivermectin, blocking transmission

Posted Date: February 9th, 2023

DOI: https://doi.org/10.21203/rs.3.rs-2561408/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Additional Declarations: No competing interests reported.
**Version of Record:** A version of this preprint was published at Parasites & Vectors on June 9th, 2023. See the published version at [https://doi.org/10.1186/s13071-023-05769-2](https://doi.org/10.1186/s13071-023-05769-2).
Abstract

Background: Microfilarial (mf) counts were monitored over 21.3 months for any rebound that might occur in counts and adulticidal efficacy was assessed following administration of low dosage with short- and long-treatment regimens of doxycycline and ivermectin to heartworm microfilaremic dogs.

Methods: Twelve heartworm-naïve Beagles infected with 10 pairs of adult Dirofilaria immitis by IV transplantation were randomly allocated to 3 groups of 4 dogs. All treatments started on Day 0. On Day 0, Group 1 (short-treatment regimen) received doxycycline orally at 10 mg/kg once daily for 30 days plus ivermectin orally (min., 6 mcg/kg) on Days 0 and 30. Group 2 (long-treatment regimen) received doxycycline orally at 10 mg/kg once daily until individual dogs became mf negative (72-98 days) and ivermectin every other week until individual dogs became mf negative (6-7 doses). Group 3 was the untreated control. Mf counts and antigen (Ag) tests were conducted. Dogs were necropsied for recovery and enumeration of heartworms on Day 647.

Results: Day -1 mean mf counts were 15,613, 23,950 and 15,513 mf/mL for Groups 1, 2 and 3, respectively. Mean counts for Group 1 and 2 declined until days 239 and 97, respectively, when all were negative. Group 3 had high mf counts throughout the study. There was not a rebound in mf counts in any of the treated dogs after they became amicrofilaremic. All dogs in Group 1 and Group 3 were Ag positive throughout the study and had at least 1 live female worm at necropsy. All dogs in treated Group 2 were positive for Ag through Day 154, but were antigen-negative on days 644 and 647, as all had only male worms.

Mean live adult worm recoveries for Groups 1, 2 and 3 were 6.8 (range, 5-8), 3.3 (range, 1-6) and 16.0 (range, 14-17), respectively, with a percent reduction in adult worm counts of 57.5% for Group 1 and 79.3% for Group 2.

Conclusions: This data lends support to the use of the American Heartworm Society Canine Guidelines for adulticide therapy recommendation of initiating doxycycline plus an ML treatment at the time of the heartworm-positive diagnosis.

Background

The Wolbachia endosymbiont, Wolbachia pipientis (Rickettsiaceae), is present in some of the most important species of filarial parasites, such as Dirofilaria immitis, Wuchereria bancrofti, Onchocerca volvulus, Brugia malayi, Brugia pahangi, Litomosoides sigmodontis and others [1–8]. Although the numbers of Wolbachia vary among individuals and life cycle stages, every individual worm in these filarial species has at least some of the bacteria [7, 9]. Wolbachia are needed for normal growth and development of these filariae and sufficient indirect and direct evidence exist that the association between the filaria and Wolbachia is obligatory, with a strong mutualistic interaction [7]. Earlier work demonstrated that tetracycline drugs had sub-lethal effects such as inhibition of embryogenesis and infertility against B. pahangi, D. immitis, L. sigmodontis, O. volvulus and Wuchereria bancrofti [10–17],
inhibition of third-stage larval development and in vivo prophylaxis against B. pahangi and L. sigmodontis [10, 13, 18], stunting of adult worm growth in L. sigmodontis [13] and B. pahangi (McCall et al., unpublished data), and even death of adult worms of O. ochengi in cattle [19], O. volvulus in humans [15] and W. bancrofti in humans [20]. There is general agreement that the antilarial effects of tetracycline therapy are a result of activity against Wolbachia because these antibiotics have no effect on the Wolbachia-negative filariae such as Acanthocheilonemiasis vitae [13, 18] and because the anti-bacterial effect precedes the anti-filarial effects (Langworthy et al., 2000 [7, 15, 16, 19].

In regard to D. immitis, the tetracycline drug doxycycline, administered with or without a macrocyclic lactone preventive, has been shown to adversely affect every life cycle stage: circulating microfilariae (mf) [3, 21–28], L3 and L4 stages [25, 29], juveniles [22, 29], young adults [22], and mature adults [21, 23–25, 27, 28, 30].

It has been shown that prolonged administration of prophylactic doses of macrocyclic lactone heartworm preventive drugs, particularly ivermectin or moxidectin, kills older larvae, immatures (juveniles), young adults and mature adults. In addition, a high percentage of dogs become amicrofilaric within a few weeks to several months after dosing is started. The rate of kill with such treatment with ivermectin is dependent on the age of the heartworms when monthly treatment is initiated, with 3-month-old larvae requiring up to 1 year and mature adults requiring 2.5 years to provide efficacy of at least 95%. This data has been summarized [31]. More recently, it has been shown that the administration of doxycycline plus prophylactic doses of ivermectin has a synergistic effect on microfilariae and adult heartworms [23]. Circulating microfilariae were eliminated more quickly when both drugs were administered (by 12 weeks) than when the drugs were administered alone (few to many months) in most dogs and adult worm efficacy was much higher at 36 weeks when both drugs were administered together (78.3%) than when doxycycline (8.7%) or ivermectin (20.3%) alone was given [24].

The American Heartworm Society recommends the initiation of daily doses of doxycycline for one month with a one-month rest period and concurrently a macrocyclic lactone preventive two months before the 3-injection protocol for melarsomine is started, with administration of both drugs starting on the same day [32–33]. The ML is expected to prevent further infection and gradually reduce microfilaricemia levels. However, circulating microfilariae can be detected in some dogs for several months after starting the administration of doxycycline or ivermectin alone or doxycycline plus an ML [24, 25, 27]. Monthly prophylactic doses of ivermectin along with a month of daily doses of doxycycline administered orally at 10 mg/kg twice daily (bid) can significantly reduce Wolbachia levels, reduce pulmonary infiltrates, reduce worm biomass, decrease post treatment complications and morbidity [32, 33], and impede the spread of ML-resistant as well as ML-susceptible heartworms [24, 25]. The additional one-month (no-treatment rest period) is hypothesized to allow for clearance of metabolites such as Wolbachia Surface Protein (WSP) and further reduction in the biomass before administration of melarsomine is started [32–34].

McCall et al. [24] demonstrated that treatment of Dirofilaria immitis microfilaricemic dogs with both doxycycline, administered orally at 10 mg/kg daily on weeks 1–6, 10–11, 16–17, 22–25, and 28–30, and
ivermectin, administered orally at 6 mcg/kg once weekly until necropsy at 36 weeks, cleared mf by 12 weeks, with no rebound in mf, and killed 78.3% of the adult heartworms. The present study was designed to monitor mf counts over a longer duration of 647 days (21.3 months) for any rebound that might occur in mf counts and assess adulticidal efficacy following administration of doxycycline and ivermectin at the same dosages as in the earlier study but in two shorter treatment regimens.

Methods

General study design

Twelve adult Beagle dogs were infected with 10 pairs of adult male and female *D. immitis* (Berkeley isolate), 1 male and 1 female per pair, by IV transplantation via a jugular vein [35]. After mf counts were greater than 1,000 mf/mL, the dogs were randomly allocated to three groups of four dogs each based on mf count. Day 0 was the first day of dosing. Starting on Day 0, Group 1 (short-treatment regimen) received doxycycline orally at approximately 10 mg/kg sid for 30 days plus a heartworm preventive dose of ivermectin (min., 6 mcg/kg) on Days 0 and 30; Group 2 (long-treatment regimen) dogs received doxycycline orally at approximately 10 mg/kg sid until each dog was mf-negative (range, 72–98 doses) and a preventive dose of ivermectin every other week for a total of 6–7 doses. Group 3 served as the untreated control. Microlaria counts (Modified Knott test) were done prior to the first day of treatment, at 1–2 week intervals during the first four months, and then monthly thereafter until necropsy. Heartworm antigen (Ag) tests (DiroCHEK™ Heartworm Antigen test Kit, Zoetis, Inc., Kalamazoo, Michigan) were done on all dogs prior to treatment, again at Days 70 and 154, and then on days 644 and 647. One untreated control dog was euthanized (with no worm count) on Day 112 due to severe heartworm disease, and the remaining 11 dogs were necropsied for recovery and enumeration of adult heartworms on Day 647.

Mosquito strain and heartworm isolate

In 1972, the Black-eyed Liverpool strain of *Aedes aegypti* used in this study was obtained by the University of Georgia from Prof. W.W. Macdonald in the Department of Parasitology and Entomology at the Liverpool School of Tropical Medicine, who had obtained it from West Africa in 1962 [36]. TRS Labs, Inc., (TRS) obtained the strain from the UGA in 1980. During the 50 years the mosquitoes were maintained at UGA and then TRS, it is estimated the strain was maintained through a total of 2,009 generations. For further details about this strain, see McCall et al. [37] in this issue.

The Berkeley isolate of *D. immitis* was used in this study. The isolate was obtained by TRS from Berkeley County, South Carolina (USA) in April 2014 and was validated by testing positive for heartworm microfilariae and antigen and by worm recovery at necropsy in December 2014. It is known to be susceptible to macrocyclic lactone (MC) heartworm preventives [38].

Animals and animal management

Twelve purpose-bred male (6) and female (6) Beagles from a commercial supplier were used in this study. They ranged in age from 1.1–1.3 years on the day of infection and ranged from 6.5–11.0 kg on
Day 0. They were born and raised indoors in mosquito-proof facilities and were not treated with any heartworm preventive drugs prior to the start of this study. They had negative test results for mf (modified Knott test) and adult heartworm Ag (DiroCHEK™ Heartworm Antigen Test Kit, Zoetis, Inc., Kalamazoo, Michigan) on Day 0 (first day of treatment) and were randomly allocated by a table of random numbers to 3 groups of 4 dogs each based on similar heartworm mf counts. The dogs were housed individually in 4 ft. by 5 ft. kennels during dosing. Thereafter, they were pair-housed by gender within groups, i.e., with access to their mate's kennel. This study was approved by the TRS Labs' Institutional Animal Care and Use Committee prior to initiation of the study and the dogs received humane care, with at least a once-daily health observation, throughout the study.

**Study drugs**

Doxycycline hyclate was administered as one 100 mg tablet or two 50 mg capsules (Harris Pharmaceuticals) orally sid to achieve a dosage of approximately 10 mg/kg/day. The daily dose range for Group 1 treated dogs was 9.1–10.9 mg/kg and the daily dose range for Group 2 treated dogs was 9.6–15.4 mg/kg.

Ivermectin was administered orally as 68 mcg chewables (Iverhart®, Virbac, Ft. Worth, Texas) to achieve a minimum dose of 6.0 mcg/kg of ivermectin. Each treated dog received one chewable per dose. The daily dose range for Group 1 treated dogs was 6.2–7.4 mcg/kg and the dose range for Group 2 treated dogs was 6.5–10.5 mcg/kg).

**Statistical analysis**

Mean mf counts between experimental groups over the course of the study was compared using a two-tailed Wilcoxon matched-pairs signed rank test with α = 0.05. A log-rank test was used to compare the time to microfilaria clearance between short- and long- treatment regimen groups.

The numbers of adult male and female worms recovered at necropsy in the short-treatment and long-treatment regimen groups were compared to those of the control group using t tests corrected with the Holm-Šídák method. All analyses were performed in Graphpad Prism 8.0 (GraphPad Software, La Jolla, CA).

**Results**

**Effects of treatment on microfilarial counts**

One untreated control dog (Group 3) was removed from the study on Day 112, so mean counts from Day 126 until the end of the study were based on values for the three remaining dogs. One day prior to the start of treatment on Day 0, mean mf counts were 15,613, 23,950 and 15,513 mf/mL for Groups 1 (short-treatment regimen), 2 (long-treatment regimen) and 3 (untreated control), respectively (Fig. 1). Mean mf counts in the treated groups either increased slightly (Group 1) or remained the same (Group 2) until Day 28. During the next two weeks, the mean mf counts in the two treated groups (Groups 1 and 2) declined
rapidly and were 4,863 and 7,525 mf/mL on Day 42, respectively, compared with a control count of 25,113 mf/mL at this time. In Group 1 (short-treatment regimen), one dog became mf negative on Day 42, a second dog became mf negative on Day 56, a third dog became mf negative on Day 97 and the fourth dog became mf negative on Day 239. Thus, all dogs in Group 1 were amicrofilaremic by Day 239 and remained amicrofilaremic throughout the remainder of the study. In Group 2 (long-treatment regimen), one dog was mf negative on Day 70, a second dog became mf negative on Day 83, and the third and fourth dogs became mf negative on Day 97. Thus, all dogs in this group became amicrofilaremic by Day 97 and remained amicrofilaremic throughout the remainder of the study. In contrast, all untreated control dogs (Group 3) had circulating mf throughout the study. Mean mf counts in this group gradually increased, with a mean mf peak count of 79,433 mf/mL on Day 436. Thereafter, the mean mf count gradually decreased to 14,683 mf/mL on Day 604 and then rose to 27,517 mf/mL just prior to necropsy on Day 647 (21.3 months).

Significant differences in mf counts were observed between both the short-treatment (mean = 2,634 mf/ml) and long-treatment (mean = 3,477 mf/ml) regimen groups and the untreated control group (mean = 32,782 mf/ml; \( p < 0.0001 \) for each). No significant difference was observed between short- and long-treatment regimen groups (\( p = 0.54 \)).

A log-rank test found no significant differences in time to mf clearance between short- and long-treatment regimen groups, with a median time to clearance of 83.5 and 90 days, respectively (\( \chi^2 = 0.066, p = 0.80 \)).

**Adult heartworm antigen levels**

As indicated in Table 1, heartworm Ag tests were conducted on Days −1, 70, 154, 642 and 647. All of the dogs in Group 1 (short-treatment regimen) and Group 3 (untreated control) were antigen-positive on all of the tests. For Group 2 (long-treatment regimen), all of the dogs were antigen-positive on Days −1, 70 and 154 but all were negative on Days 642 and 647.

**Recovery of heartworms at necropsy**

As shown in Table 2, all dogs were infected by IV transplantation of 10 pairs of adult male and female heartworms, with each pair consisting of 1 male and 1 female worm (total, 20 heartworms/dog). At necropsy, one or two dead female worms were recovered from two dogs in Group 1. No dead worms were recovered from dogs in Groups 2 and 3. In regard to live heartworms, all dogs in Group 1 (short treatment regimen) had live male and female heartworms, with a mean of 6.8 worms per dog and a range of 5–8. All dogs had 1 or 2 live female heartworms plus at least 4 live male worms (range, 4–6). Adult worm efficacy for this group was 57.5%. For Group 2 (long treatment regimen), none of the 4 dogs had any live adult female heartworms, while all of the dogs had live adult male heartworms, with a mean of 3.3 worms per dog (range, 1–6 worms/dog). Adult worm efficacy for this group was 79.4%. In comparison, all of the 3 untreated control dogs (Group 3) had live adult heartworms, with a mean of 16.0 worms per dog (range, 14–17). Each dog in this group had at least 8 male and 5 female heartworms.
The numbers of adult male and female worms recovered from animals in the short treatment regimen group (Group 1) were significantly fewer than those from the untreated control group (Group 3) \((p < 0.001\) and \(p < 0.004\), respectively). Similarly, significantly fewer male and female worms were recovered from the long treatment regimen group (Group 2) compared to the control group (Group 3) \((p < 0.019\) and \(p < 0.0009\), respectively).

**Discussion**

For heartworm adulticidal therapy, the American Heartworm Society currently recommends the administration of daily, oral doses of doxycycline administered at 10 mg/kg bid for 28 days and a ML heartworm preventive drug, with dosing of both drugs starting on the same day two months before the first injection of the 3-injection protocol for melarsomine is given [33]. While the doxycycline plus ML treatment will eventually clear mf from the blood, some mf have been shown to persist for up to 3 weeks following administration of high-dose topical moxidectin (1.0 mL or 2.5 mL of IMD + moxidectin by labeled microfilaricidal dosage and administration for 10 months) plus oral doxycycline (10.0-14.1 mg/kg, min., 10 mg/kg bid) for 30 days) [27] and up to 5.5 months following initiation of daily doses of doxycycline (10 or 5 mg/kg bid for 28 days) and 6 monthly prophylactic doses of ivermectin plus pyrantel pamoate (min., 6 mcg/kg ivermectin by label dosage administration) [28]. In both of these studies, once all of the dogs in the treated groups became amicrofilaric, there was not a rebound in circulating mf thereafter. However, examination for mf in both of these studies was discontinued relatively early (5.5–8.2 months) after dosing was started. It seems possible that a rebound might have been detected if the studies had been continued for a longer period. In the current study, which used half the dosage of doxycycline and shorter ML treatment periods, circulating mf continued to persist for 239 days in one of the four dogs after the short-treatment regimen of doxycycline (30 days) and two monthly prophylactic doses of ivermectin were initiated. Moreover, mf continued to circulate for up to 97 days in one of the four dogs on the long-treatment regimen of doxycycline and 6–7 bi-weekly prophylactic doses of ivermectin. However, once the treated dogs became amicrofilaric, there was no rebound in circulating mf for the remainder of the 647-day (20.3 months) study. These observations indicate that even the low dosages and short-treatment regimen of doxycycline and ivermectin used in the short-treatment regimen group, which received less doxycycline (i.e., one-half the daily dosage and a similar treatment length) and the same dosage in a shorter ML treatment regimen than the Savadelis et al. study [28], were sufficient to prevent a rebound in mf counts for over 20 months. The earlier clearance of mf in the long-treatment regimen group in the current study can be attributed to the longer treatment with doxycycline and ivermectin. The earlier clearance of circulating mf in the Savadelis et al. [27] study than in the current study can be attributed to the use of high-dose doxycycline plus high-dose moxidectin, which is an approved heartworm microfilaricide [39].

In regard to efficacy against adult heartworms, mean recoveries for the short-treatment regimen (Group 1), long-treatment regimen (Group 2) and untreated controls (Group 3) were 6.8, 3.3 and 16.0, respectively (Table 1). Adult worm recoveries were significantly reduced in both the short- and long- treatment regimen groups when compared to the untreated controls. Moreover, worm recoveries in the two treated groups
were substantially, but not statistically, different from each other. In addition, there was a gender effect in the two treated groups. No live female worms were recovered from dogs in the long-treatment regimen group, whereas all dogs in the short-treatment regimen group had one or two live female worms. Also, about twice as many male worms were recovered from the short-treatment regimen group as from the long-treatment regimen group. Considering the larger size, more worm tissue invaded and destroyed by the *Wolbachia* and presumably more dead *Wolbachia* in female worms than in male worms [9, 40], it seems reasonable to assume that the longer treatment regimen resulted in a higher death rate of *Wolbachia*, which are generally considered necessary for long-term survival of the worms. This probably led to a higher death rate in the female worms.

It is noteworthy that no gender effect was noted in the Savadelis et al. [27] study. Moreover, adulticidal efficacy was higher in the Savadelis et al. [27] study than in the current study. It seems plausible that the difference in the two studies might be due to differences in the ML and dosage level/regimen length used, the dosage of doxycycline used and/or the duration of the study. In that study, a total of only one male worm was recovered from the treated group, while a total of four females was recovered and the overall efficacy of treatment was 95.9%. The Savadelis et al. [27] study used a higher doxycycline dosage of 10 mg/kg bid for 30 days and more (10 monthly) treatments of the ML (high-dose, microfilaricidal moxidectin), while a lower dosage of 10 mg/kg sid for 30 days and 2 monthly doses of low-dose (prophylactic) ivermectin (short-treatment regimen) or a lower dosage of 10 mg/kg sid for 72–98 days and 6–7 biweekly doses of low-dose (prophylactic) ivermectin (long-treatment regimen) were used in the current study. Adulticidal efficacy in the current study was 57.5% for the low-dose, short-treatment regimen group compared to 79.4% for the low-dose, long-treatment regimen group. The higher adulticidal efficacy obtained with the longer treatment regimen for both drugs in the current study can be attributed to the more drug given for a longer period of time. The higher adulticidal efficacy seen in the Savadelis et al. [27] study was probably due to the use of a higher dosage of doxycycline and high-dose moxidectin.

**Conclusion**

Even when the low dosages and short-treatment regimens of both doxycycline (10 mg/kg sid for 30 days) and ivermectin (min. dose of 6 mcg/kg on Days 0 and 30) were administered to heartworm-microfilaremic dogs (Group 1), once the dogs became mf negative there was no rebound in the count for at least 647 days (21.3 months). And, with the long-treatment regimen of both doxycycline (10 mg/kg sid daily) and ivermectin (min. dosage of 6 mcg/kg every other week until each dog became amicrofilaremic), there was complete elimination of adult female heartworms and a substantial reduction in male heartworms at necropsy. The earlier clearance of mf from the blood and the higher adulticidal efficacy obtained with the longer treatment regimen for both drugs in the current study can be attributed to more of both drugs being given and the long holding period after treatment.

The data in this study lends further support to the use of the American Heartworm Society Canine Guidelines for adulticidal therapy recommendation of initiating doxycycline plus an ML treatment at the same time as the heartworm-positive diagnosis.
Declarations

Acknowledgements

The authors acknowledge the assistance of Ashley Warren, Lauren Sullivan, April Lamy, Rob Desso, Austin McCall, and Sharon Carter. The authors also deeply appreciate Chris Evans providing the Statistical Analysis.

Funding

TRS Labs, Inc.

Availability of data and materials

Not applicable

Authors’ Contributions

JWM: Conceptualization, methodology, writing—original draft, writing—review and editing. AM: parasitology and laboratory assistance, writing—review and editing. UD: parasitology and laboratory assistance, writing—review and editing. CF: Veterinary care and procedures, writing—review and editing. SM: project administration, research coordinator, product administration. MTD: Adult heartworm transplantation, writing—review. BC: Laboratory technical assistance, product administration.

Ethics approval and consent to participate

The TRS Labs’ Institutional Animal Care and Use Committee approved the study prior to implementation.

Consent for publication

All of the authors approved the manuscript before submission.

Competing interests

None of the authors have any competing interests in this study.

References


37. McCall JW, DiCosty U, Mansour A, Fricks C, McCall S, Dzimianski MT, et al. Inability of *Dirofilaria immitis* infective larvae from mosquitoes fed on blood from microfilaremic dogs during low-dose and short-treatment regimen doxycycline and ivermectin treatment to complete normal development in heartworm naïve dogs. Parasites and Vectors. 2023;xx;xxxxx(in this issue)


**Tables**

Table 1 is available in the Supplementary Files section.

Table 2 is not available with this version

**Figures**
Fig. 1  Mean microfilarial counts for dogs. All treatments started on Day 0. Group 1 dogs (short-treatment regimen) were administered doxycycline orally at 10 mg/kg sid for 30 days plus ivermectin orally (min. dose, 6 mcg/kg) on Days 0 and 30. Group 2 dogs (long-treatment regimen) were administered doxycycline orally at 10 mg/kg sid until individual dogs became amicrofilaremic (72-98 days) and ivermectin every two weeks until individual dogs became amicrofilaremic (6-7 doses). Group 3 dogs were the untreated control. Group 1 and 2 dogs became microfilaria negative on Days 239 and 97, respectively, and remained negative through Day 647.

Figure 1

See image above for figure legend.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- McCalletalLongtermevalTable1.pdf
- McCalletalLongtermevalTitleofTable1.pdf